Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors

Details Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors

2007-05-24

2008-11-25

Coleman, Brenda L (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C540S576000

Reexamination Certificate

active

07456167

ABSTRACT:
The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

REFERENCES:
patent: 7153848 (2006-12-01), Hudyma et al.
patent: 2006/0166964 (2006-07-01), Hudyma et al.
patent: 2007/0060565 (2007-03-01), Meanwell et al.
patent: 2007/0078122 (2007-04-01), Bergstrom et al.
patent: 2007/0185083 (2007-08-01), Bergstrom et al.
patent: WO2005/080399 (2005-09-01), None
patent: WO2006/040039 (2006-04-01), None
patent: WO2006/046030 (2006-05-01), None
patent: WO2007/029029 (2007-03-01), None
U.S. Appl. No. 11/752,354, filed May 23, 2007, Robert G. Gentles, et al.
U.S. Appl. No. 11/753,137, filed May 24, 2007, Carl P. Bergstrom.
U.S. Appl. No. 11/756,203, filed May 31, 2007, Kap-Sun Yeung, et al.

Affiliated with

Also associated with

Rating

Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4020773